Clinical Trials Logo

Staphylococcal Skin Infections clinical trials

View clinical trials related to Staphylococcal Skin Infections.

Filter by:

NCT ID: NCT01026636 Completed - Clinical trials for Staphylococcal Skin Infections

A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age

Start date: August 2007
Phase: Phase 1
Study type: Interventional

This study will assess the pharmacokinetics (how drugs are absorbed, distributed in the body and removed over time) and safety of a single dose of ceftobiprole in pediatric patients undergoing treatment with systemic antibiotics and may be used to guide dosing recommendations for ceftobiprole in children.

NCT ID: NCT01026558 Completed - Obesity Clinical Trials

A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients

Start date: August 2007
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to compare the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of ceftobiprole in morbidly obese patients and non-obese patients. The secondary objectives are to assess the pharmacodynamics (the study of the action or effects a drug has on the body) and to assess safety and tolerability of ceftobiprole in order to support dosing recommendations in the morbidly obese population.

NCT ID: NCT01018641 Completed - Clinical trials for Bacterial Infections

An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

Start date: January 2010
Phase: Phase 1
Study type: Interventional

This study is a first-in-human (Phase 1) study using three dose levels of an investigational vaccine directed against Staphylococcus aureus (SA3Ag). This study is primarily designed to assess how safe and well tolerated SA3Ag is, but will also describe the immune response over 12 months elicited by SA3Ag. Additionally, this study will assess the effect of SA3Ag vaccine on the number of Staphylococcus aureus bacteria that naturally occur on the skin and within the nose and throat.

NCT ID: NCT00737269 Completed - Clinical trials for Surgical Wound Infection

A Complicated Skin and Soft-tissue Infection Patient Registry

Start date: June 2008
Phase: Phase 4
Study type: Observational

The purpose of this registry is to better understand (1) complicated skin and soft-tissue infections requiring hospitalization, and (2) clinical and economic outcomes in hospitalized patients receiving intravenous antibiotic therapy.

NCT ID: NCT00731783 Completed - Clinical trials for Staphylococcus Aureus

Staphylococcus Aureus Decolonization Study

SuDS
Start date: July 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether measures to eliminate the Staph germ from the skin of the index patient (with a special ointment and soap) are more effective when performed by everyone in the household rather than the patient alone, and whether these methods are effective in preventing future Staph infections. The investigators hypothesize that there will be a greater number of households who are successful in eradicating the staph germ from the index patient when all members of the household participate than households where only the index patient is treated.

NCT ID: NCT00719810 Completed - Clinical trials for Staphylococcal Skin Infections

Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections

Start date: June 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, safety and tolerability of RX-3341 (delafloxacin), a fluoroquinolone, versus tigecycline, a glycylcycline antibacterial drug, in the treatment of complicated skin and skin structure infections.

NCT ID: NCT00646958 Completed - Abscess Clinical Trials

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

Start date: December 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy, safety and tolerability of RX-1741, an oxazolidinone, versus linezolid, another oxazolidinone, in the treatment of uncomplicated skin and skin structure infections

NCT ID: NCT00560599 Completed - Clinical trials for Methicillin Resistant Staphylococcus Aureus Skin Infections

A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection

PRIMO
Start date: April 2007
Phase: Phase 3
Study type: Interventional

This clinical trial tests the hypotheses that 1) body decolonization of patients with recurrent community-associated (CA) MRSA infections and their household members and 2) environmental decolonization of the patients' households will significantly reduce the likelihood of recurrent CA-MRSA infection.

NCT ID: NCT00514527 Completed - Wounds and Injuries Clinical Trials

A Study for Patients With Complicated Skin and Skin Structure Infections

SIMPLIFI
Start date: August 2007
Phase: Phase 2
Study type: Interventional

Two Phase III trials to demonstrate the efficacy and safety of oritavancin in the treatment of complicated skin and skin structure infections (cSSSI) have been completed. The pharmacokinetic profile of oritavancin in humans suggests that oritavancin has the potential to be used safely and effectively when given either as a single dose or as an infrequent dose for cSSSI. Data from animals support this theory. SIMPLIFI has been designed to evaluate the efficacy and safety of either a single dose of oritavancin or an infrequent dose of oritavancin (First dose on Day one with an option for a second dose on Day five) compared to the previously studied dosing regimen of 200mg oritavancin given once daily for 3 to 7 days.

NCT ID: NCT00513799 Completed - Clinical trials for Staphylococcus Aureus

The Natural History of Community-Associated MRSA Infections and Decolonization Strategies

StLStaRS
Start date: March 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the natural history of community-associated Staphylococcus aureus infections in both adult and pediatric patients by monitoring the rate of recurrent infections in those colonized with S. aureus. In addition, this study will evaluate the efficiency of commonly prescribed decolonization measures in patients presenting with S. aureus skin and soft tissue infections.